Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of MacugenÂ® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.